Redhill Biopharma (RDHL) Stock Price, News & Analysis

Company Overview

RedHill Biopharma Ltd. (NASDAQ:RDHL) is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally administered drugs for the treatment of gastrointestinal and inflammatory diseases, oncology and infectious diseases. The company’s core strategy centers on the acquisition and advancement of late-stage clinical candidates, leveraging its expertise in small-molecule chemistry and regulatory pathways to bring novel therapies to market.

Among RedHill’s leading products is Talicia®, an FDA‐approved combination therapy for the treatment of Helicobacter pylori infection, which represents a significant advancement over existing regimens. The company’s clinical pipeline includes RHB-104, a Phase 3 candidate for Crohn’s disease, and opaganib®, an orally delivered, first-in-class sphingosine kinase-2 inhibitor being investigated for COVID-19 and oncology indications. Additionally, RedHill is pursuing the development of RHB-107 (upamostat) for pancreatic and colorectal cancers, demonstrating its commitment to addressing high-unmet-need conditions.

Founded in 2003 and headquartered in Raleigh, North Carolina, with research and development activities in Israel, RedHill Biopharma operates in key global markets, including the United States and Europe. The company has established strategic partnerships to support the commercialization and distribution of its products in multiple territories. RedHill’s operational footprint combines a lean corporate structure with networked collaborations, enabling efficient advancement of its pipeline while managing development costs.

RedHill Biopharma is led by a seasoned management team with extensive experience in pharmaceutical research, regulatory affairs and commercial execution. Under the leadership of President and CEO Ron Najafi, the company continues to pursue a focused clinical development plan, aiming to deliver differentiated therapies that address critical patient needs. As RedHill advances its late-stage candidates toward regulatory approval and market launch, the company remains dedicated to strengthening its product portfolio and expanding its global reach.

Key Stats

• Today's Range: $2.11 to $2.19
• 50-Day Range: $1.75 to $2.19
• 52-Week Range: $1.71 to $20.28
• Volume: 11,495 shs
• Average Volume: 164,778 shs
• Market Capitalization: $5.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RDHL Stock Analysis - Frequently Asked Questions

How have RDHL shares performed this year?

Redhill Biopharma's stock was trading at $6.21 at the start of the year. Since then, RDHL stock has decreased by 64.7% and is now trading at $2.19.

How were Redhill Biopharma's earnings last quarter?

Redhill Biopharma Ltd. (NASDAQ:RDHL) issued its quarterly earnings results on Tuesday, November, 30th. The biotechnology company reported ($500.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($480.00) by $20.00. The biotechnology company earned $21.61 million during the quarter, compared to the consensus estimate of $23.41 million.

When did Redhill Biopharma's stock split?

Shares of Redhill Biopharma reverse split on the morning of Tuesday, August 20th 2024.The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 19th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Redhill Biopharma?

Shares of RDHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Redhill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Redhill Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CymaBay Therapeutics (CBAY) and AbbVie (ABBV).

Company Calendar

• Last Earnings: 11/30/2021
• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RDHL
• Previous Symbol: ASX:RDH
• CIK: 1553846
• Web: www.redhillbio.com
• Phone: 972-3541-3131
• Fax: 972-3541-3144
• Employees: 210
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.54
• Quick Ratio: 0.37

Sales & Book Value

• Annual Sales: $8.04 million
• Price / Sales: 0.63
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.66) per share
• Price / Book: -0.60

Miscellaneous

• Outstanding Shares: 2,300,000
• Free Float: 2,139,000
• Market Cap: $5.04 million
• Optionable: No Data
• Beta: 4.22